Lifeboat Foundation

“For those who have lost their ability to communicate due to a variety of neurological conditions, there’s a lot of hope to preserve or regain their ability to communicate with family and friends.”

The term “brain-computer interface” (BCI) refers to a technology that creates a direct line of communication between the human brain and an outside object or computer system, opening up a wide range of possibilities for things like device control and neurological study.

Oonal/iStock.

Continue reading “ALS patients control home devices with their minds using BCI” »

“High-risk mothers in many parts of rural India are usually identified in the third trimester, which is around the eighth month of pregnancy. However, by this time, it’s often too late to manage complications before labour. This can lead to fatal outcomes,” says Senthil Kumar Murugesan.

An electronics and communications engineer by profession, Senthil is trying to bridge this gap with JioVio Healthcare, an IoT-based maternal healthcare startup that provides early-risk monitoring services at home.

He first encountered the pregnancy healthcare gap when his sister was pregnant in 2016. She is a career-driven woman and would miss her antenatal appointments due to the lack of time. Also, the… More.

Continue reading “This Portable Innovation Saves Lives by Bringing Doctors to 30 Lakh Pregnant Women” »

High Microsatellite Instability is an emerging biomarker for immune-oncology that can be predictive of positive response to immunotherapy.

Tumors with defects in the expression of functional MMR (dMMR) proteins often have somatic mutations that produce novel or “foreign” proteins. These proteins can be immunogenic. As a result, these tumors are effective at priming an immune response and subsequently susceptible to immunotherapies. Because MSI can be the first evidence of an MMR deficiency, MSI-H status is predicative of a positive response to immunotherapies such as immune checkpoint blockade inhibitors.

In America, roughly 40 million Americans have diabetes and about 95% of them have type 2 diabetes. Type 2 diabetes occurs when the body cannot correctly process sugar and fuel cells. More specifically, the body does not produce enough insulin to break down sugar into glucose for the cells to use. In this case, treatment includes insulin shots or a pump in addition to a strict diet excluding sweets or high fat meals. Treatment limitations disrupt patient quality of life. Some researchers have been working on better detection for diabetic retinopathy with artificial intelligence (AI), but research is limited on how to better detect diabetes itself. Thus, many researchers are working to detect diabetes early on and discover better treatments.

Klick labs, located in multiple cities across the world, is trying to detect type 2 diabetes by having a patient speak into a microphone for 10 seconds. Klick labs believes this technology can better detect diabetes and help patients get treatment earlier. The study was published in Mayo Clinic Proceedings: Digital Health, which details how patients spoke for 10 seconds and combined with health data, including age, sex, height, and weight, created an AI model that discerns whether a person has type 2 diabetes or not. After further tests, scientists determined it has 89% and 86% accuracy for women and men, respectively.

In the study, Klick Labs collected voice recordings of 267 people, either non-diabetic or diabetic. The participants were asked to record a phrase into their smartphones six times a day for a total of 2-weeks. Over 18,000 recordings were taken and analyzed to distinguish 14 acoustic features that helped distinguish non-diabetic to type 2 diabetic individuals. The research highlights specific vocal variations in pitch and intensity that could lead to how the medical community screens for early-onset diabetes. A major barrier to early detection includes time, travel, and cost, which many people do not have. Voice diagnosis can help eliminate those barriers and improve detection and treatment in diabetic patients.

Scientists have made remarkable progress in understanding the underlying changes that make cancer grow and have applied this knowledge to develop and guide targeted treatment approaches to vastly improve outcomes for people with many cancer types. And yet treatment progress for people with brain tumors known as gliomas—including the most aggressive glioblastomas—has remained slow. One reason is that doctors lack tests that reliably predict which among many therapeutic options will work best for a given tumor.

Now an NIH-funded team has developed a miniature device with the potential to change this for the approximately 25,000 people diagnosed with brain cancers in the U.S. each year [1]. When implanted into cancerous brain tissue during surgery, the rice-sized drug-releasing device can simultaneously conduct experiments to measure a tumor’s response to more than a dozen drugs or drug combinations. What’s more, a small clinical trial reported in Science Translational Medicine offers the first evidence in people with gliomas that these devices can safely offer unprecedented insight into tumor-specific drug responses [2].

These latest findings come from a Brigham and Women’s Hospital, Boston, team led by Pierpaolo Peruzzi and Oliver Jonas. They recognized that drug-screening studies conducted in cells or tissue samples in the lab too often failed to match what happens in people with gliomas undergoing cancer treatment. Wide variation within individual brain tumors also makes it hard to predict a tumor’s likely response to various treatment options.

How safe are our routers? Japan & U.S. cybersecurity agencies have flagged a major threat in the form of China’s BlackTech group.

Learn more about the threat:

BlackTech, a notorious state-backed hackers from China, are using router backdoors to quietly to breach government, tech, and media sectors in the U.S.

A highly unstable nucleus that decays by emitting five protons has been observed, offering an extreme case for testing nuclear models.

Researchers have found evidence of an extremely unstable nucleus for which more than half of the component particles are unbound, meaning that they are not tightly connected to the dense core of the nucleus [1]. The nucleus, nitrogen-9, is composed of a small helium-like core surrounded by five untethered protons that quickly escape after the nucleus’s formation. Previous experiments have seen at most four unbound protons in a nucleus. The research team had to carefully sift through a large volume of nuclear-collision data to identify the nitrogen-9 decays. This barely bound nucleus poses a unique challenge to theories of nuclear structure.

A nucleus with a large imbalance between its numbers of protons and neutrons is less stable than one in which the numbers are similar. In the extreme cases, these proton-or neutron-rich isotopes are unbound, meaning that one or more nucleons escape during decay. The boundaries between bound and unbound states—both on the proton-rich and on the neutron-rich sides of the nuclear landscape—are called drip lines. Researchers are interested in finding nuclei beyond the drip lines because they offer tests of models at the limits of nuclear existence. These exotic nuclei may also play a role in the formation of heavy elements in supernovae and in neutron star mergers.

A single-layer transition-metal dichalcogenide on top of a silver film displays strong light–matter coupling without the need for nanostructures or microcavities.

For those with stubbornly resistant forms of severe depression, ketamine was looking more and more like a solution. Years of research has hinted at the dissociative anesthetic’s treatment potential where other medications failed, promising the benefits of electroshock therapy with far fewer risks.

For all of the excitement, separating the hope from the hype has been challenged by the drug’s strong psychoactive effects. How can you conduct a blind test for a drug that so overtly detaches the mind from the body?

By taking advantage of the unconscious state of patients under general anesthesia, researchers from Stanford University School of Medicine in the US put ketamine to the ultimate, gold standard test.